EC Status and Availability

South Korea

Registered LNG-EC products:

  • After-1 - Available only with prescription
  • Levonia - Available only with prescription
  • Levonormin - Available only with prescription
  • MS Pill - Available only with prescription
  • Norlevo One* - Available only with prescription
  • Postinor 1* - Available only with prescription

Registered UPA-EC products:

  • ellaOne* - Available only with prescription

Products marked with * have been approved by a stringent regulatory authority, such as the WHO Prequalification Programme, the US Food and Drug Administration, the European Medicines Agency, or other.

Where at least one type of ECP is available: Pharmacies, IPPF-affiliated system

Age restrictions for accessing ECPs: No data available

Legal history, developments, and/or challenges: EC currently still requires a prescription. Although in August 2012 the Korean Food and Drug Administration (KFDA) decided to repeal an earlier initiative that would have approved EC for over-the-counter use, due to intense debate within the country among various stakeholders, the KFDA abandoned the reclassification initiative.

Legal/regulatory documents in which EC is included: No data available

Other relevant information: EC distributed via IPPF outlets (<500 in 2012).

Our country-by-country information comes from numerous sources, including partners from around the world. We have made every effort to ensure that the information included here is correct, but EC availability and policies can change quickly. We welcome your additions and/or corrections

To submit updates and corrections to ICEC, click here.

Begin a new search